Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study.

Antimicrobial resistance Carbapenem resistance Carbapenemases Cefiderocol Clinical practice

Journal

Infectious diseases and therapy

ISSN: 2193-8229

Titre abrégé: Infect Dis Ther

Pays: New Zealand

ID NLM: 101634499

Informations de publication

Date de publication:
12 Jul 2024

Historique:

received: 22 05 2024

accepted: 27 06 2024

medline: 12 7 2024

pubmed: 12 7 2024

entrez: 12 7 2024

Statut: aheadofprint

Résumé

Cefiderocol is a siderophore cephalosporin showing activity against various carbapenem-resistant Gram-negative bacteria (CR-GNB). No data currently exist about real-world use of cefiderocol in terms of types of therapy (e.g., empirical or targeted, monotherapy or combined regimens), indications, and patient characteristics. In this multicenter, prospective study, we aimed at describing the use of cefiderocol in terms of types of therapy, indications, and patient characteristics. Cefiderocol was administered as empirical and targeted therapy in 27.5% (55/200) and 72.5% (145/200) of cases, respectively. Overall, it was administered as monotherapy in 101/200 cases (50.5%) and as part of a combined regimen for CR-GNB infections in the remaining 99/200 cases (49.5%). In multivariable analysis, previous isolation of carbapenem-resistant Acinetobacter baumannii odds ratio (OR) 2.56, with 95% confidence interval (95% CI) 1.01-6.46, p = 0.047] and previous hematopoietic stem cell transplantation (OR 8.73, 95% CI 1.05-72.54, p = 0.045) were associated with administration of cefiderocol as part of a combined regimen, whereas chronic kidney disease was associated with cefiderocol monotherapy (OR 0.38 for combined regimen, 95% CI 0.16-0.91, p = 0.029). Cumulative 30-day mortality was 19.8%, 45.0%, 20.7%, and 22.7% in patients receiving targeted cefiderocol for infections by Enterobacterales, A. baumannii, Pseudomonas aeruginosa, and any metallo-β-lactamase producers, respectively. Cefiderocol is mainly used for targeted treatment, although empirical therapies account for more than 25% of prescriptions, thus requiring dedicated standardization and guidance. The almost equal distribution of cefiderocol monotherapy and cefiderocol-based combination therapies underlines the need for further study to ascertain possible differences in efficacy between the two approaches.

Identifiants

DOI: 10.1007/s40121-024-01016-y PMID: 38995601

pubmed: 38995601

doi: 10.1007/s40121-024-01016-y

pii: 10.1007/s40121-024-01016-y

doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Shionogi

ID : 2021-IIR-000047

Investigateurs

Ylenia Murgia (Y)

Gabriele Di Meco (G)

Alice Cappello (A)

Sabrina Guastavino (S)

Cristina Campi (C)

Michele Piana (M)

Sara Mora (S)

Nicola Rosso (N)

Antonio Di Biagio (A)

Giulia Viglietti (G)

Iole Brunetti (I)

Chiara Robba (C)

Lorenzo Ball (L)

Denise Battaglini (D)

Federica Portunato (F)

Maddalena Giannella (M)

Pierluigi Viale (P)

Giulia Viero (G)

Cecilia Azzarà (C)

Alessandro Bartoloni (A)

Benedetta Casciato (B)

Chiara Grillo (C)

Donatella Cibelli (D)

Silvia Boni (S)

Marcello Feasi (M)

Paola Del Giacomo (P)

Gianmaria Baldin (G)

Federico D'Amico (F)

Giovanna Travi (G)

Teresa Fasciana (T)

Giulia Catalisano (G)

Antonino Giarratano (A)

Elena Baranello (E)

Margherita Albagini (M)

Chiara Maci (C)

Antonella Castagna (A)

Cecilia Grosso (C)

Nour Shbaklo (N)

Elena Momesso (E)

Nicoletta Boffa (N)

Elena Potenza (E)

Vincenzo Scaglione (V)

Daniele Mengato (D)

Alessandro Russo (A)

Ludovica Corsello (L)

Francesca Serapide (F)

Monica Rizzo (M)

Erika Asperges (E)

Francesco Truffelli (F)

Margherita Sambo (M)

Gabriele Giuliano (G)

Francesco Fele (F)

Chiara Gullotta (C)

Edoardo Campanella (E)

Maria Chiara Meloni (MC)

Sabrina Boraso (S)

Sandro Panese (S)

Aurora Bonazza (A)

Kristian Scolz (K)

Erika Coppo (E)

Marco Berruti (M)

Informations de copyright

Références

Ong’uti S, Czech M, Robilotti E, et al. Cefiderocol: a new cephalosporin stratagem against multidrug-resistant gram-negative bacteria. Clin Infect Dis. 2022;74(7):1303–12.

pubmed: 34492098 doi: 10.1093/cid/ciab757

Giacobbe DR, Ciacco E, Girmenia C, et al. Evaluating cefiderocol in the treatment of multidrug-resistant gram-negative bacilli: a review of the emerging data. Infect Drug Resist. 2020;13:4697–711.

pubmed: 33402840 pmcid: 7778378 doi: 10.2147/IDR.S205309

Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21(2):213–25.

pubmed: 33058798 doi: 10.1016/S1473-3099(20)30731-3

Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18(12):1319–28.

pubmed: 30509675 doi: 10.1016/S1473-3099(18)30554-1

Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226–40.

pubmed: 33058795 doi: 10.1016/S1473-3099(20)30796-9

Timsit JF, Paul M, Shields RK, et al. Cefiderocol for the treatment of infections due to metallo-B-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 randomized studies. Clin Infect Dis. 2022;75(6):1081–4.

pubmed: 35148378 pmcid: 9522395 doi: 10.1093/cid/ciac078

Falcone M, Tiseo G, Leonildi A, et al. Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2022;66(5): e0214221.

pubmed: 35311522 doi: 10.1128/aac.02142-21

Falcone M, Tiseo G. Cefiderocol for the treatment of metallo-beta-lactamases producing gram-negative bacilli: lights and shadows from the literature. Clin Infect Dis. 2022;75(6):1085–7.

pubmed: 35136982 doi: 10.1093/cid/ciac082

Bassetti M, Di Pilato V, Giani T, et al. Treatment of severe infections due to metallo-beta-lactamases-producing Gram-negative bacteria. Future Microbiol. 2020;3:1489–505.

doi: 10.2217/fmb-2020-0210

Zingg S, Nicoletti GJ, Kuster S, et al. Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: real-world Experience From a Case Series and Review of the Literature. Open Forum Infect Dis. 2020;7(6): ofaa185.

pubmed: 32548207 pmcid: 7284008 doi: 10.1093/ofid/ofaa185

Wicky PH, Poiraud J, Alves M, et al. Cefiderocol treatment for severe infections due to difficult-to-treat-resistant non-fermentative gram-negative bacilli in ICU patients: a case series and narrative literature review. Antibiotics (Basel). 2023;12(6):991.

pubmed: 37370310 pmcid: 10295316 doi: 10.3390/antibiotics12060991

Russo A, Bruni A, Gulli S, et al. Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19. Int J Antimicrob Agents. 2023;62(1): 106825.

pubmed: 37088438 pmcid: 10121149 doi: 10.1016/j.ijantimicag.2023.106825

Rando E, Cutuli SL, Sangiorgi F, et al. Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. baumannii ventilator-associated pneumonia: a propensity-weighted cohort study. JAC Antimicrob Resist. 2023;5(4): dlad085.

pubmed: 37484029 pmcid: 10359102 doi: 10.1093/jacamr/dlad085

Piccica M, Spinicci M, Botta A, et al. Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience. J Antimicrob Chemother. 2023;78(11):2752–61.

pubmed: 37807834 pmcid: 10631827 doi: 10.1093/jac/dkad298

Pascale R, Pasquini Z, Bartoletti M, et al. Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study. JAC Antimicrob Resist. 2021;3(4): dlab174.

pubmed: 34806011 pmcid: 8599913 doi: 10.1093/jacamr/dlab174

Palermo G, Medaglia AA, Pipito L, et al. Cefiderocol efficacy in a real-life setting: single-centre retrospective study. Antibiotics (Basel). 2023;12(4):746.

pubmed: 37107108 doi: 10.3390/antibiotics12040746

Meschiari M, Volpi S, Faltoni M, et al. Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections. JAC Antimicrob Resist. 2021;3(4): dlab188.

pubmed: 34909691 pmcid: 8665210 doi: 10.1093/jacamr/dlab188

Mazzitelli M, Gregori D, Sasset L, et al. Cefiderocol-based versus colistin-based regimens for severe carbapenem-resistant Acinetobacter baumannii infections: a propensity score-weighted, retrospective cohort study during the first two years of the COVID-19 pandemic. Microorganisms. 2023;11(4):984.

pubmed: 37110408 pmcid: 10146662 doi: 10.3390/microorganisms11040984

Lupia T, Carnevale-Schianca F, Vita D, et al. Stenotrophomonas maltophilia infections in haematological malignancies and hematopoietic stem cell transplantation: a case series including cefiderocol-based regimens. Medicina (Kaunas). 2024;60(1):88.

pubmed: 38256349 doi: 10.3390/medicina60010088

Larcher R, Laffont-Lozes P, Roger C, et al. Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: a real-life study. Front Cell Infect Microbiol. 2022;12:1048633.

pubmed: 36544909 pmcid: 9762507 doi: 10.3389/fcimb.2022.1048633

Karruli A, Massa A, Andini R, et al. Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience. Int J Antimicrob Agents. 2023;61(2): 106723.

pubmed: 36642233 doi: 10.1016/j.ijantimicag.2023.106723

Hoellinger B, Simand C, Jeannot K, et al. Real-world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting, gram negative bacilli infections: a case series. Clin Microbiol Infect. 2023;29(3):393–5.

pubmed: 36410645 doi: 10.1016/j.cmi.2022.11.005

Giannella M, Verardi S, Karas A, et al. Carbapenem-resistant Acinetobacter spp infection in critically ill patients with limited treatment options: a descriptive study of cefiderocol therapy during the COVID-19 pandemic. Open Forum Infect Dis. 2023;10(7): ofad329.

pubmed: 37496600 pmcid: 10368198 doi: 10.1093/ofid/ofad329

Gavaghan V, Miller JL, Dela-Pena J. Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections. Infection. 2023;51(2):475–82.

pubmed: 36201152 doi: 10.1007/s15010-022-01933-5

Fendian AM, Albanell-Fernandez M, Tuset M, et al. Real-life data on the effectiveness and safety of cefiderocol in severely infected patients: a case series. Infect Dis Ther. 2023;12(4):1205–16.

pubmed: 36943617 pmcid: 10029777 doi: 10.1007/s40121-023-00776-3

Falcone M, Tiseo G, Nicastro M, et al. Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant gram-negative infections in intensive care unit patients. Clin Infect Dis. 2021;72(11):2021–4.

pubmed: 32941593 doi: 10.1093/cid/ciaa1410

El Ghali A, Kunz Coyne AJ, Lucas K, et al. Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections. Microbiol Spectr. 2024;12(2): e0310823.

pubmed: 38206034 doi: 10.1128/spectrum.03108-23

de la Fuente C, Rodriguez M, Merino N, et al. Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2023;62(1): 106818.

pubmed: 37062445 doi: 10.1016/j.ijantimicag.2023.106818

Dalfino L, Stufano M, Bavaro DF, et al. Effectiveness of first-line therapy with old and novel antibiotics in ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii: a real life, prospective, observational, single-center study. Antibiotics (Basel). 2023;12(6):1048.

pubmed: 37370367 pmcid: 10295543 doi: 10.3390/antibiotics12061048

Corcione S, De Benedetto I, Pinna SM, et al. Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key? J Infect Public Health. 2022;15(9):975–9.

pubmed: 35961239 doi: 10.1016/j.jiph.2022.07.006

Chou A, Ramsey D, Amenta E, et al. Real-world experience with cefiderocol therapy for Pseudomonas aeruginosa and other multidrug resistant gram-negative infections within the Veterans Health Administration, 2019–2022. Antimicrob Steward Healthc Epidemiol. 2023;3(1): e90.

pubmed: 37179761 pmcid: 10173288 doi: 10.1017/ash.2023.165

Campogiani L, Crea AMA, Minardi ML, et al. Real-life data on cefiderocol efficacy and safety to treat multidrug-resistant Acinetobacter baumannii infections. Open Forum Infect Dis. 2023;10(12): ofad627.

pubmed: 38156051 pmcid: 10753918 doi: 10.1093/ofid/ofad627

Calo F, Onorato L, De Luca I, et al. Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: a multicenter observational study. J Infect Public Health. 2023;16(9):1485–91.

pubmed: 37349243 doi: 10.1016/j.jiph.2023.06.009

Bavaro DF, Papagni R, Belati A, et al. Cefiderocol versus colistin for the treatment of carbapenem-resistant Acinetobacter baumannii complex bloodstream infections: a retrospective, propensity-score adjusted. Monocentric Cohort Study Infect Dis Ther. 2023;12(8):2147–63.

pubmed: 37653122 doi: 10.1007/s40121-023-00854-6

Balandin B, Pintado V, Perez-Pedrero MJ, et al. Multicentre study of cefiderocol for treatment of Gram-negative bacteria infections in critically ill patients. Int J Antimicrob Agents. 2024;63(5): 107121.

pubmed: 38408494 doi: 10.1016/j.ijantimicag.2024.107121

Hackel MA, Tsuji M, Yamano Y, et al. Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth. Diagn Microbiol Infect Dis. 2019;94(4):321–5.

pubmed: 31029489 doi: 10.1016/j.diagmicrobio.2019.03.003

Bartoletti M, Giannella M, Lewis R, et al. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. Clin Microbiol Infect. 2018;24(5):546e1–8.

doi: 10.1016/j.cmi.2017.08.001

Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–51.

pubmed: 7722560 doi: 10.1016/0895-4356(94)90129-5

Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707–10.

pubmed: 8844239 doi: 10.1007/BF01709751

Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.

pubmed: 26903338 pmcid: 4968574 doi: 10.1001/jama.2016.0287

Force ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526–33.

Kellum JA, Lameire N, Group KAGW. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1):204.

pubmed: 23394211 pmcid: 4057151 doi: 10.1186/cc11454

CDC/NHSN Surveillance Definitions for Specific Types of Infections [last accessed 24 March 2024]. https://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf .

Blaker H. Confidence curves and improved exact confidence intervals for discrete distributions. Can J Statistics. 2000;28:783–98.

doi: 10.2307/3315916

Pereira CA de B, Polpo A. MedOr: Order of Medians Based on Confidence Statements. arXiv.org 2012. http://arxiv.org/abs/1212.5405 .

Yuan YC. Multiple Imputation for Missing Data: Concepts and New Development (Version 9.0). SAS Institute Inc.; 2010 [last accessed 27 Mar 2023]. Available at: https://support.sas.com/rnd/app/stat/papers/multipleimputation.pdf .

Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America guidance on the treatment of ampc beta-lactamase-producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clin Infect Dis. 2022;74(12):2089–114.

pubmed: 34864936 doi: 10.1093/cid/ciab1013

Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum beta-lactamase producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022;75(2):187–212.

pubmed: 35439291 pmcid: 9890506 doi: 10.1093/cid/ciac268

Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521–47.

pubmed: 34923128 doi: 10.1016/j.cmi.2021.11.025

Cortegiani A, Ingoglia G, Ippolito M, et al. Empiric treatment of patients with sepsis and septic shock and place in therapy of cefiderocol: a systematic review and expert opinion statement. J Anesth Analg Crit Care. 2022;2(1):34.

pubmed: 37386663 pmcid: 9361889 doi: 10.1186/s44158-022-00062-7

Tiseo G, Brigante G, Giacobbe DR, et al. Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). Int J Antimicrob Agents. 2022;60(2): 106611.

pubmed: 35697179 doi: 10.1016/j.ijantimicag.2022.106611

Onorato L, de Luca I, Monari C, et al. Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. J Infect. 2024;88(3): 106113.

pubmed: 38331328 doi: 10.1016/j.jinf.2024.01.012

Oliva A, Liguori L, Covino S, et al. Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study. Eur J Clin Microbiol Infect Dis. 2024;43(6):1149–60.

pubmed: 38634975 pmcid: 11178648 doi: 10.1007/s10096-024-04833-8

Gatti M, Cosentino F, Giannella M, et al. Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis. Int J Antimicrob Agents. 2024;63(2): 107047.

pubmed: 38061418 doi: 10.1016/j.ijantimicag.2023.107047

Gill K, Takamichi B, Cooper A. Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: new data from CREDIBLE-CR with an updated meta-analysis. International Journal of Antimicrobial Agents. 2024 2024/04/04/:107167.

Gatti M, Cosentino F, Giannella M, et al. In reply to the Letter to the Editor regarding “Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis”. Int J Antimicrob Agents. 2024:107168.

Karakonstantis S, Rousaki M, Vassilopoulou L, et al. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis. Clin Microbiol Infect. 2024;30(2):178–88.

pubmed: 37666449 doi: 10.1016/j.cmi.2023.08.029

Giacobbe DR, Marelli C, Cattardico G, et al. Mortality in KPC-producing Klebsiella pneumoniae bloodstream infections: a changing landscape. J Antimicrob Chemother. 2023;78(10):2505–14.

pubmed: 37606528 doi: 10.1093/jac/dkad262